Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 242-248

  McLeod, Olga ^a   Silveira, Angela ^a   Fredrikson, Gunilla N ^c   Gertow, Karl ^a   Baldassarre, Damiano ^d   Veglia, Fabrizio ^d   Sennblad, Bengt ^b   Strawbridge, Rona J ^a   Larsson, Malin ^a   Leander, Karin ^a   Gigante, Bruna ^a   Kauhanen, Jussi ^f   Rauramaa, Rainer ^f   Smit, Andries J ^g   Mannarino, Elmo ^h   Giral, Philippe ⁱ   Humphries, Steve E ^e   Tremoli, Elena ^d   de Faire, Ulf ^a   Öhrvik, John ^a   Nilsson, Jan ^c   Hamsten, Anders ^a   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Carotid ultrasound; Intima media thickness; Malondialdehyde modified apoB 100 peptide 210; Native apoB 100 peptide 210; Progression

Indexed keywords

APOLIPOPROTEIN B100 ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MALONALDEHYDE ANTIBODY; P210 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; FEMALE; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

CAROTID ULTRASOUND; INTIMA-MEDIA THICKNESS; MALONDIALDEHYDE-MODIFIED APOB-100 PEPTIDE 210; NATIVE APOB-100 PEPTIDE 210; PROGRESSION;

AGED; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; AUTOANTIBODIES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; DISEASE PROGRESSION; EPITOPES; EUROPE; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MALONDIALDEHYDE; MIDDLE AGED; PEPTIDES; RISK FACTORS; TIME FACTORS;

EID: 84891720846     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.11.041     Document Type: Article

References (29)

1. Nilsson J., Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing controlα. JIntern Med 2008, 263:464-478.
2. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
3. Ketelhuth D.F., Tonini G.C., Carvalho M.D., Ramos R.F., Boschcov P., Gidlund M. Autoantibody response to chromatographic fractions from oxidized LDL in unstable angina patients and healthy controls. Scand J Immunol 2008, 68:456-462.
4. Binder C.J. Natural IgM antibodies against oxidation-specific epitopes. JClin Immunol 2010, 30(Suppl.1):S56-S60.
5. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. Tlymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92:3893-3897.
6. Fredrikson G.N., Hedblad B., Berglund G., et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003, 23:872-878.
7. Nilsson J., Hansson G.K., Shah P.K. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005, 25:18-28.
8. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
9. Goncalves I., Nitulescu M., Ares M.P., et al. Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions. Atherosclerosis 2009, 205:96-100.
10. Hansson G.K., Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2009, 29:1714-1717.
11. Palinski W., Miller E., Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995, 92:821-825.
12. Ameli S., Hultgardh-Nilsson A., Regnstrom J., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996, 16:1074-1079.
13. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:108-114.
14. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
15. Sun J., Hartvigsen K., Chou M.Y., et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation 2010, 122:808-820.
16. Wigren M., Kolbus D., Duner P., et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. JIntern Med 2011, 269:546-556.
17. Gasparyan A.Y., Stavropoulos-Kalinoglou A., Mikhailidis D.P., Toms T.E., Douglas K.M., Kitas G.D. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharm 2010, 8:437-449.
18. Klingenberg R., Lebens M., Hermansson A., et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:946-952.
19. Fredrikson G.N., Schiopu A., Berglund G., Alm R., Shah P.K., Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007, 194:e188-192.
20. Fredrikson G.N., Hedblad B., Berglund G., et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007, 38:1495-1500.
21. Sjogren P., Fredrikson G.N., Samnegard A., et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008, 29:2218-2226.
22. Fredrikson G.N., Anand D.V., Hopkins D., et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009, 52:1426-1433.
23. Baldassarre D., Nyyssonen K., Rauramaa R., et al. Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. Eur Heart J 2010, 31:614-622.
24. Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997, 18:1231-1248.
25. Beux F., Carmassi S., Salvetti M.V., et al. Automatic evaluation of arterial diameter variation from vascular echographic images. Ultrasound Med Biol 2001, 27:1621-1629.
26. Renauda O., Victoria-Feserb M.-P. Arobust coefficient of determination for regression. JStat Plan Inference 2010, 140:1852-1862.
27. Tibshirani R., Friedman J.H. The elements of statistical learning: data mining, inference, and prediction. Springer series in statistics 2009, Springer, New York, NY. 2nd ed.
28. Huber P.J. Robust estimation of a location parameter. Ann Math Stat 1964, 35:73-101.
29. Purcell S., Neale B., Todd-Brown K., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.